A 54-amino-acid peptide (with active fragments of 10-54 residues) encoded by the KiSS-1 gene that is the master upstream regulator of the reproductive hormone axis. Kisspeptin neurons in the hypothalamus directly control GnRH pulse generation — determining puberty onset, fertility, and reproductive function.
Kisspeptin is a peptide product of the KiSS-1 gene that serves as the master upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Kisspeptin neurons in the arcuate nucleus of the hypothalamus directly stimulate GnRH neurons, controlling the pulsatile release of GnRH that drives the entire reproductive hormone cascade.
The name 'kisspeptin' comes from the KiSS-1 gene, which was named after Hershey Kisses chocolates because the gene was discovered in Hershey, Pennsylvania (as a metastasis suppressor gene, initially called metastin). Its critical role in reproduction was discovered when loss-of-function mutations in its receptor (GPR54/KISS1R) were found to cause hypogonadotropic hypogonadism — absence of puberty.
Kisspeptin is a remarkable example of how a single peptide can control an entire physiological system. The kisspeptin-GnRH-gonadotropin cascade is the master switch for puberty: when kisspeptin neurons in the hypothalamus begin firing (triggered by reaching a critical body mass and metabolic state), they activate GnRH neurons, which in turn stimulate LH and FSH release from the pituitary, initiating the hormonal cascade of puberty. Mutations in the kisspeptin receptor (KISS1R/GPR54) cause hypogonadotropic hypogonadism — patients fail to enter puberty entirely — demonstrating kisspeptin's essential role.
Clinically, kisspeptin is being investigated as a more physiological alternative to GnRH agonists for fertility treatment. By stimulating the body's own GnRH release rather than directly flooding GnRH receptors, kisspeptin may produce a more natural pattern of gonadotropin release and reduce the risk of ovarian hyperstimulation syndrome (OHSS) in IVF protocols. Phase II trials at Imperial College London and other centers have shown promising results for kisspeptin in triggering oocyte maturation during IVF.
Kisspeptin is also being studied for its role in psychosexual function — it enhances sexual and romantic brain processing in both men and women, independent of its reproductive hormone effects. This has opened a new avenue of research into kisspeptin as a potential treatment for psychosexual disorders.
Kisspeptin binds to GPR54 (KISS1R), a Gq-coupled GPCR exclusively expressed on GnRH neurons in the hypothalamus. Activation triggers PLC-IP3-Ca²⁺ signaling, depolarizing GnRH neurons and causing GnRH release into the portal blood system. The pulsatile pattern of kisspeptin release (driven by the kisspeptin-neurokinin B-dynorphin (KNDy) neuron network) directly determines the pulsatile pattern of GnRH — which is essential for normal LH/FSH secretion.
| Pathway | Effect | Significance |
|---|---|---|
| GnRH activation | Direct stimulation of GnRH neurons via GPR54 | Master control of the entire reproductive hormone cascade |
| Puberty trigger | Increased kisspeptin expression at puberty onset | Determines timing of sexual maturation |
| LH surge | Kisspeptin from AVPV neurons triggers preovulatory LH surge | Essential for ovulation in females |
| Metabolic gating | Kisspeptin neurons sense leptin, insulin, and energy status | Links nutritional status to reproductive capacity (why underweight → amenorrhea) |
| Stress integration | Cortisol suppresses kisspeptin neurons | Explains stress-induced infertility and amenorrhea |
| Study | Design | Findings | Level |
|---|---|---|---|
| Genetic proof | Human genetics | Loss-of-function mutations in KISS1R cause hypogonadotropic hypogonadism (no puberty). Gain-of-function causes precocious puberty. Definitive proof of function. | Level I (genetic) |
| Fertility treatment | Phase II trials, n=various | Kisspeptin-54 injection triggers LH release in healthy women and men. Being studied as a safer alternative to hCG for IVF trigger. | Level II |
| Hypothalamic amenorrhea | Clinical studies | Kisspeptin infusion restores LH pulsatility in women with hypothalamic amenorrhea | Level II |
| Male hypogonadism | Phase I/II | Kisspeptin injection increases testosterone in men with functional hypogonadism | Level II |
Clinical trial safety: In published Phase I and Phase II trials, kisspeptin has been well-tolerated with no serious adverse events reported at doses used for fertility applications. The most common side effect is a transient feeling of warmth or flushing, consistent with its vasoactive properties.
Short duration of action: Kisspeptin has a very short half-life (approximately 28 minutes for kisspeptin-54, even shorter for shorter fragments), which is advantageous for safety — effects are transient and rapidly reversible — but limits its utility for chronic administration without modified-release formulations.
No OHSS risk reduction: One of kisspeptin's key potential advantages over GnRH agonists in IVF is reduced OHSS risk, though this requires confirmation in larger trials.
Investigational status: Kisspeptin remains an investigational compound with no regulatory approvals for any indication worldwide. It is available through clinical trials but not through compounding pharmacies or commercial channels.
| Jurisdiction | Status |
|---|---|
| FDA | Not approved. Clinical trials ongoing for IVF applications. |
| Research | One of the most active areas of reproductive endocrinology research |
| Significance | Potential to replace hCG trigger in IVF (lower OHSS risk) and treat functional hypothalamic amenorrhea |